The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human trial focusing on the immunologic effects of the survivin-derived multiepitope vaccine EMD640744.
S. Gross
No relevant relationships to disclose
V. Lennerz
No relevant relationships to disclose
E. Gallerani
No relevant relationships to disclose
C. Sessa
Research Funding - Merck Serono
N. Mach
No relevant relationships to disclose
S. Boehm
No relevant relationships to disclose
D. Hess
No relevant relationships to disclose
L. von Boehmer
No relevant relationships to disclose
A. Knuth
No relevant relationships to disclose
A. Ochsenbein
No relevant relationships to disclose
U. Gnad-Vogt
Consultant or Advisory Role - Merck Serono
J. Zieschang
Employment or Leadership Position - Merck KGaA
U. Forssmann
Employment or Leadership Position - Merck Serono
T. Woelfel
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Research Funding - Merck Serono
E. Kaempgen
Consultant or Advisory Role - Merck KGaA
Research Funding - Merck KGaA